Navigation Links
Reimbursement systems influence achievement of cholesterol targets
Date:8/31/2013

Dr Gitt said: "There are wide variations between European countries in the achievement of LDL-cholesterol (LDL-C) targets. However the effect of different reimbursement systems on meeting the targets was unknown."

Between June 2008 and February 2009 DYSIS assessed the prevalence and types of persistent lipid abnormalities in patients receiving statins. Eligible patients were at high risk of a cardiovascular event, aged >45 years, and had been on chronic statin treatment for at least three months. A total of 22,063 patients were enrolled from 2,954 sites across 11 European countries and Canada.

The current subanalysis examined the possible impact of reimbursement systems on the achievement of LDL-C targets in 4,260 German patients and 540 UK patients. Germany operates a "restrictive" system in which chronic medical treatment is restricted by budget constraints. In the UK's incentive system, reimbursement of general practitioners (GPs) is linked to achieving cholesterol targets.

Dr Gitt said: "The bottom line is that German doctors fear a punitive system where they could be fined if they don't stay within budget while UK doctors get rewarded for achieving targets."

The study found that just 42% of German patients achieved the target of LDL-C <100mg/dl compared to 79.8% of UK patients (p<0.001). Dr Gitt said: "Twice as many UK patients achieve cholesterol target levels as German patients. By definition of the study protocol all patients had been on statin treatment. As there are no differences in the availability of lipid lowering drugs between both countries, the different health care systems might have an impact on the way patients are treated."

Atorvastatin (a potent statin) was used in 3.9% of German patients (mean dose 24.0 mg) compared to 24.8% of UK patients (mean dose 34.2 mg) (p<0.01). Simvastatin (a weaker statin) was used in 83.9% of Germans (mean dose 27.2 mg) compared to 67.6% of UK patients (mean dose 36.6 mg) (p<0.01). Daily dosages were significantly lower in Germany than in the UK, independent of the statin used.

Dr Gitt said: "We found that UK patients are treated with more potent statins and higher doses. UK doctors are treating patients aggressively with statins in response to a financial incentive to reach cholesterol targets. German doctors treat more conservatively, less often using potent statins and high doses which are more expensive."

He added: "The quality control feedback system in the UK may also impact on the achievement of cholesterol targets. GPs have to measure cholesterol levels and this identifies which patients need more aggressive treatment to reach the target."

Dr Gitt concluded: "Our study showed that healthcare reimbursement systems appear to impact on the achievement of cholesterol lowering targets. The German system was put in place to control costs but it remains to be seen whether it will achieve this in the long term. The UK system has higher short term costs, with more GP visits, use of potent statins and high doses, but it may ultimately be more cost effective because of fewer complications."


'/>"/>

Contact: Celine Colas
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. PPACA Hospital Reimbursements Impacted by HCAHPS Patient Satisfaction: RateHospitals.com Empowers Patients to Define Healthcare's Future
2. Zane Benefits Publishes New Information on Reimbursement of Health Insurance Premiums
3. Zane Benefits Publishes New Information on Section 105 Medical Reimbursement Plans
4. Zane Benefits Publishes New Information on Health Reimbursement Arrangements
5. Zane Benefits Publishes New Information on Health Reimbursement Medical Plans
6. TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans
7. Zane Benefits Publishes New Information on Health Reimbursement Accounts
8. Digital Health Funding, Sensors, DNA, Big Data, and Reimbursement Hot Topics at Living in Digital Times' Digital Health Summer Summit
9. Zane Benefits Publishes New Information on Health Reimbursement Arrangements
10. Zane Benefits Publishes New Information on Health Reimbursement Arrangements for Small Businesses
11. Zane Benefits Publishes New Information on Health Care Reimbursement Accounts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... awareness and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics ... 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a ...
(Date:4/29/2016)... Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... Monday, May 16, 2016, at its new location in the Exchange Furniture Mall at ... a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... the $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition ... Michelson People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... 2016   , ... Recurring Consumable Sales  Clinical sales grow 16% ... (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... the first quarter ended March 31, 2016 and provided ... its commercial strategy. First Quarter 2016 Revenue ...
Breaking Medicine Technology: